1-15 of 140
Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
CME/CEContinuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
Christian Mende, MD, FACP, FACN, FASN, FASH, FAHA
Deepak Bhatt, MD, MPH, MBA, FACC, FAHA
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CENavigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CEVous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Patient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
CME/CEPatient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
Jay B. Wish, MD
- advertisement
Richard Lafayette, MD, FACP
Dana Rizk, MD
Hong Zhang
Suzuki Yusuke, MD, PhD
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
MinuteCE®The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
Richard Lafayette, MD, FACP
Dana Rizk, MD
Hong Zhang
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®Mechanism-Based Targeting: Why APRIL Matters in IgAN
Suzuki Yusuke, MD, PhD
Dana Rizk, MD
Dana Rizk, MD
Suzuki Yusuke, MD, PhD
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Hong Zhang
- advertisement
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®Emerging Evidence: IgAN Disease-Modifying Agents
Richard Lafayette, MD, FACP
Hong Zhang
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®Emerging Therapies in IgAN: Who Could Benefit the Most?
Richard Lafayette, MD, FACP
Hong Zhang
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Richard Lafayette, MD, FACP
Suzuki Yusuke, MD, PhD
